A successful treatment of rheumatoid arthritis-related interstitial pneumonia with nintedanib
Rheumatoid arthritis-related interstitial pneumonia with a usual interstitial pneumonia (RA-UIP) has a poor prognosis and a new treatment strategy is required. The antifibrotic agent nintedanib reduces the annual rate of decline in forced vital capacity (FVC) in idiopathic pulmonary fibrosis (IPF) p...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-01-01
|
| Series: | Respiratory Medicine Case Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213007118303344 |
| _version_ | 1818300879677161472 |
|---|---|
| author | Tamaki Kakuwa Shinyu Izumi Keita Sakamoto Tomoyuki Suzuki Motoyasu Iikura Haruhito Sugiyama |
| author_facet | Tamaki Kakuwa Shinyu Izumi Keita Sakamoto Tomoyuki Suzuki Motoyasu Iikura Haruhito Sugiyama |
| author_sort | Tamaki Kakuwa |
| collection | DOAJ |
| description | Rheumatoid arthritis-related interstitial pneumonia with a usual interstitial pneumonia (RA-UIP) has a poor prognosis and a new treatment strategy is required. The antifibrotic agent nintedanib reduces the annual rate of decline in forced vital capacity (FVC) in idiopathic pulmonary fibrosis (IPF) patients. Recently, the potential efficacy of antifibrotic agents against chronic progressive fibrotic diseases including RA-UIP has been attracting attention.A 74-year-old man diagnosed with IPF on high-resolution computed tomography (HRCT). His FVC was decreasing over time, and his exertional dyspnea and cough had progressed with progression of reticulation on imaging. He was treated with nintedanib, which resulted in decreased coughing together with a reduction in FVC decline, from −11.6%/year to −5.2%/year. A swollen joint appeared eight months after this intervention, and he was diagnosed with rheumatoid arthritis.In this patient, nintedanib was effective against RA-UIP. This is the first case in which nintedanib was shown to be effective for RA-UIP. |
| first_indexed | 2024-12-13T05:14:08Z |
| format | Article |
| id | doaj.art-811e297a7c3549b094abae72057b7911 |
| institution | Directory Open Access Journal |
| issn | 2213-0071 |
| language | English |
| last_indexed | 2024-12-13T05:14:08Z |
| publishDate | 2019-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Respiratory Medicine Case Reports |
| spelling | doaj.art-811e297a7c3549b094abae72057b79112022-12-21T23:58:27ZengElsevierRespiratory Medicine Case Reports2213-00712019-01-01265052A successful treatment of rheumatoid arthritis-related interstitial pneumonia with nintedanibTamaki Kakuwa0Shinyu Izumi1Keita Sakamoto2Tomoyuki Suzuki3Motoyasu Iikura4Haruhito Sugiyama5Corresponding author.; Department of Respiratory Medicine, National Center for Global Health and Medicine, JapanDepartment of Respiratory Medicine, National Center for Global Health and Medicine, JapanDepartment of Respiratory Medicine, National Center for Global Health and Medicine, JapanDepartment of Respiratory Medicine, National Center for Global Health and Medicine, JapanDepartment of Respiratory Medicine, National Center for Global Health and Medicine, JapanDepartment of Respiratory Medicine, National Center for Global Health and Medicine, JapanRheumatoid arthritis-related interstitial pneumonia with a usual interstitial pneumonia (RA-UIP) has a poor prognosis and a new treatment strategy is required. The antifibrotic agent nintedanib reduces the annual rate of decline in forced vital capacity (FVC) in idiopathic pulmonary fibrosis (IPF) patients. Recently, the potential efficacy of antifibrotic agents against chronic progressive fibrotic diseases including RA-UIP has been attracting attention.A 74-year-old man diagnosed with IPF on high-resolution computed tomography (HRCT). His FVC was decreasing over time, and his exertional dyspnea and cough had progressed with progression of reticulation on imaging. He was treated with nintedanib, which resulted in decreased coughing together with a reduction in FVC decline, from −11.6%/year to −5.2%/year. A swollen joint appeared eight months after this intervention, and he was diagnosed with rheumatoid arthritis.In this patient, nintedanib was effective against RA-UIP. This is the first case in which nintedanib was shown to be effective for RA-UIP.http://www.sciencedirect.com/science/article/pii/S2213007118303344 |
| spellingShingle | Tamaki Kakuwa Shinyu Izumi Keita Sakamoto Tomoyuki Suzuki Motoyasu Iikura Haruhito Sugiyama A successful treatment of rheumatoid arthritis-related interstitial pneumonia with nintedanib Respiratory Medicine Case Reports |
| title | A successful treatment of rheumatoid arthritis-related interstitial pneumonia with nintedanib |
| title_full | A successful treatment of rheumatoid arthritis-related interstitial pneumonia with nintedanib |
| title_fullStr | A successful treatment of rheumatoid arthritis-related interstitial pneumonia with nintedanib |
| title_full_unstemmed | A successful treatment of rheumatoid arthritis-related interstitial pneumonia with nintedanib |
| title_short | A successful treatment of rheumatoid arthritis-related interstitial pneumonia with nintedanib |
| title_sort | successful treatment of rheumatoid arthritis related interstitial pneumonia with nintedanib |
| url | http://www.sciencedirect.com/science/article/pii/S2213007118303344 |
| work_keys_str_mv | AT tamakikakuwa asuccessfultreatmentofrheumatoidarthritisrelatedinterstitialpneumoniawithnintedanib AT shinyuizumi asuccessfultreatmentofrheumatoidarthritisrelatedinterstitialpneumoniawithnintedanib AT keitasakamoto asuccessfultreatmentofrheumatoidarthritisrelatedinterstitialpneumoniawithnintedanib AT tomoyukisuzuki asuccessfultreatmentofrheumatoidarthritisrelatedinterstitialpneumoniawithnintedanib AT motoyasuiikura asuccessfultreatmentofrheumatoidarthritisrelatedinterstitialpneumoniawithnintedanib AT haruhitosugiyama asuccessfultreatmentofrheumatoidarthritisrelatedinterstitialpneumoniawithnintedanib AT tamakikakuwa successfultreatmentofrheumatoidarthritisrelatedinterstitialpneumoniawithnintedanib AT shinyuizumi successfultreatmentofrheumatoidarthritisrelatedinterstitialpneumoniawithnintedanib AT keitasakamoto successfultreatmentofrheumatoidarthritisrelatedinterstitialpneumoniawithnintedanib AT tomoyukisuzuki successfultreatmentofrheumatoidarthritisrelatedinterstitialpneumoniawithnintedanib AT motoyasuiikura successfultreatmentofrheumatoidarthritisrelatedinterstitialpneumoniawithnintedanib AT haruhitosugiyama successfultreatmentofrheumatoidarthritisrelatedinterstitialpneumoniawithnintedanib |